Black phosphorus / toxicity Cancer Research Results

BP, Black phosphorus: Click to Expand ⟱
Features:
Black phosphorus (BP) has attracted considerable attention in cancer research—not only as a material for bioimaging and phototherapy but also for its ability to modulate various cellular signaling pathways.

Black phosphorus (BP), a two-dimensional nanomaterial, exhibits excellent light-absorption performance, high photothermal conversion efficiency, biodegradability, and large specific surface area. BP can be gradually degraded into phosphate ions under physiological conditions without biological toxicity. BP has shown great potential in the biomedical field for PTT, PDT, and SDT applications.

Black phosphorus — Black phosphorus (BP) is an elemental phosphorus allotrope typically developed for oncology as a two-dimensional nanomaterial, most often as black phosphorus nanosheets or black phosphorus quantum dots. It functions primarily as a stimulus-responsive theranostic platform rather than a conventional cytotoxic drug, enabling photothermal, photodynamic, sonodynamic, cargo-delivery, and radiosensitizing strategies. Formal classification is inorganic 2D nanomaterial / nanomedicine platform. Standard abbreviations include BP, BPNSs, and BPQDs. In biomedical systems it is generally produced by exfoliation or nanofabrication from bulk black phosphorus and is valued for high surface area, strong NIR absorbance, tunable surface chemistry, and degradation toward phosphate/phosphorus oxide species. The clinically relevant framing is that most anticancer activity reported to date is platform-dependent and often requires external triggers or loaded agents rather than relying on a single intrinsic drug-like mechanism.

Primary mechanisms (ranked):

  1. Stimulus-triggered photothermal conversion causing localized tumor hyperthermia and ablation.
  2. Stimulus-triggered ROS generation for photodynamic or sonodynamic tumor injury, often amplified by composite designs.
  3. Nanocarrier-mediated delivery of chemotherapeutics, nucleic acids, or immunomodulators with tumor-localized release.
  4. Redox disruption in cancer cells, including glutathione depletion and secondary oxidative stress in some engineered BP systems.
  5. DNA damage response interference and radiosensitization in selected BPQD models.
  6. Immune microenvironment modulation after local tumor destruction or combinatorial payload release.

Bioavailability / PK relevance: BP is not a standard oral agent. Anticancer studies usually use intratumoral, intravenous, implant/coating, hydrogel, or other local-delivery formats. Major PK constraints are rapid oxidation/degradation in oxygenated and aqueous environments, variable colloidal stability, protein-corona effects, and dependence on surface functionalization for circulation time and tumor retention.

In-vitro vs systemic exposure relevance: Many in-vitro cancer studies use BP concentrations and external triggers that are not directly comparable to unformulated systemic exposure. For triggered modalities, efficacy is not purely concentration-driven because NIR light, ultrasound, radiation, or composite engineering are often required. Bare-BP cytotoxicity is generally weaker than composite or externally activated systems.

Clinical evidence status: Preclinical. The oncology literature is dominated by in-vitro and rodent studies, with no established regulatory approval or routine clinical cancer deployment identified for BP nanomedicine. Current relevance is as an experimental nanoplatform and adjunct-enabling material, not as a validated human anticancer therapy.

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Photothermal conversion ↑ thermal injury / apoptosis / ablation ↔ to ↓ with targeting; can ↑ injury if off-target heating occurs P/R Core tumor-killing axis Most central translational mechanism; usually requires NIR irradiation and formulation that preserves BP stability.
2 ROS generation under NIR or ultrasound ↑ oxidative injury ↔ to ↑ injury (context-dependent) P/R PDT / SDT cytotoxicity ROS generation is often modest with bare BP and is commonly enhanced by hybridization, surface modification, oxygen-supplying, or catalytic partners.
3 Drug and gene delivery platform ↑ intratumoral payload delivery ↓ systemic exposure possible R/G Combination leverage Large surface area and functionalization enable loading of DOX, cisplatin-class agents, siRNA, and immunomodulators; effect is platform-dependent rather than intrinsic to elemental BP.
4 Glutathione depletion and redox collapse ↓ GSH ↔ to ↓ (model-dependent) R Redox sensitization Mechanistically relevant mainly in engineered BP systems, especially composites that consume GSH and amplify ROS-mediated therapy.
5 Mitochondrial ROS increase ↑ mitochondrial stress ↔ to ↑ (context-dependent) R Apoptotic amplification Usually secondary to phototherapy, sonodynamic activation, or redox-active composite design rather than a universal pristine-BP effect.
6 DNA damage repair and DNA-PKcs axis ↓ NHEJ repair; ↑ persistent DSB signaling ↔ unknown R/G Radiosensitization Supported in BPQD renal carcinoma models, where BPQDs inhibited DNA-PKcs activity and prolonged radiation-induced DNA damage.
7 Inflammation and immune microenvironment ↑ immunogenic cell death / ↑ CD8 infiltration / ↓ suppressive myeloid tone ↔ to beneficial tissue response (model-dependent) G Adjunct immune activation Often emerges after local PTT/PDT/SDT or NO-enabled therapy; not yet a stand-alone validated immunotherapy mechanism.
8 Nitric oxide axis ↑ NO-mediated stress (requires engineered system) ↔ R Gas-therapy amplification Relevant for BP composites carrying L-Arg or related NO-generating elements; not a general intrinsic property of bare BP.
9 Chemosensitization / radiosensitization ↑ response to chemo or IR ↔ to ↑ collateral toxicity (context-dependent) R/G Adjunct therapy enhancement Frequently stronger than BP monotherapy in published models; leverages thermal, redox, delivery, or DNA repair effects.
10 Clinical Translation Constraint ↓ reproducibility across models ↓ certainty of safety margin G Limits deployment Rapid degradation, batch variability, need for external triggers, local-delivery bias, uncertain long-term biodistribution/toxicity, and lack of human oncology trials remain the dominant barriers.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
toxicity, toxicity: Click to Expand ⟱
Source:
Type:
Toxicity
Scientific Papers found: Click to Expand⟱
1603- Cu,  BP,  SDT,    Glutathione Depletion-Induced ROS/NO Generation for Cascade Breast Cancer Therapy and Enhanced Anti-Tumor Immune Response
- in-vitro, BC, 4T1 - in-vivo, NA, NA
GSH↓, Fenton↑, ROS↑, NO↑, sonoS↑, eff↑, NO↑, *toxicity∅, eff?,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Fenton↑, 1,   GSH↓, 1,   ROS↑, 1,  

Transcription & Epigenetics ⓘ

sonoS↑, 1,  

Angiogenesis & Vasculature ⓘ

NO↑, 2,  

Drug Metabolism & Resistance ⓘ

eff?, 1,   eff↑, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

toxicity∅, 1,  
Total Targets: 1

Scientific Paper Hit Count for: toxicity, toxicity
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:281  Target#:1025  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page